18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma

The purpose of this study is to explore whether 18F-FDG PET/CT guided reduced-dose radiotherapy would maintain survival outcomes in nasopharyngeal carcinoma (NPC) patients.

Trial Details

NCT ID
NCT04813705
Phase
PHASE2
Sponsor
Taizhou Hospital
Status
RECRUITING
Cancer Type
Nasopharyngeal Head and Neck Cancer
Interventions
  • Reduced dose
  • Conventional dose
  • Chemotherapy
Locations (sample)
  • Taizhou, Zhejiang, China|28.66266,121.43312
  • Taizhou, Zhejiang, China|28.66266,121.43312
  • Taizhou, Zhejiang, China|28.66266,121.43312
  • Taizhou, Zhejiang, China|28.66266,121.43312

Key Eligibility Criteria

  • Pathology confirmed nasopharyngeal squamous cell carcinoma.
  • Stage I-IVA(8thAJCC/UICC staging system).
  • Aged 18-80 years.
  • Have measurable lesions on 18F-FDG PET/CT before treatment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Nasopharyngeal Head and Neck Cancer Trials on Trialify →